Breaking News, Collaborations & Alliances

BARDA Exercises Aeolus Options

Lung-ARS countermeasure pact extended

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

The Biomedical Advanced Research and Development Authority (BARDA) exercised $6.0 million in additional contract options with Aeolus Pharmaceuticals under their advanced R&D contract for AEOL-10150. BARDA is a division of the U.S. Department of Health and Human Services that manages the advanced development and purchase of medical countermeasures for public health threats. Aeolus is developing AEOL-10150 as a treatment for the pulmonary syndrome of Acute Radiation Syndrome (Lung-ARS) and de...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters